Archives of Plastic Surgery

Korean Society of Plastic and Reconstructive Surgeons (대한성형외과학회)
권호 표지

In-vivo Studies on Effect of Lipo-PGE1 on Neoangiogenesis of Composite Graft in a Rabbit Model

가토모델에서 Lipo-PGE1이 복합조직이식편의 미세혈관신생에 미치는 영향

  • Park, Ji-Ung (Departments of Plastic and Reconstructive Surgery, Dongguk University Ilsan Hospital) ;
  • Eo, Su-Rak (Departments of Plastic and Reconstructive Surgery, Dongguk University Ilsan Hospital) ;
  • Cho, Sang-Hun (Departments of Plastic and Reconstructive Surgery, Dongguk University Ilsan Hospital) ;
  • Choi, Jong-Sun (Departments of Pathology, Dongguk University Ilsan Hospital) ;
  • Kim, Eo-Jin (Departments of Pathology, Dongguk University Ilsan Hospital)
  • 박지웅 (동국대학교 의과대학 일산병원 성형외과학교실) ;
  • 어수락 (동국대학교 의과대학 일산병원 성형외과학교실) ;
  • 조상헌 (동국대학교 의과대학 일산병원 성형외과학교실) ;
  • 최종순 (동국대학교 의과대학 일산병원 병리학교실) ;
  • 김어진 (동국대학교 의과대학 일산병원 병리학교실)
  • Received : 2010.02.26
  • Accepted : 2010.04.26
  • Published : 2010.11.10
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The survival of composite graft is dependent on three steps, (1) plasmatic imbibitions, (2) inosculation, and (3) neovascularization. Among the many trials to increase the survival rate of composite graft, prostaglandin E1 (PGE1) has beneficial effects on the microcirculatory level with vasodilating, antithrombotic, anti-inflammatory and neoangiogenic properties. Lipo-PGE1 which is lipid microspheres containing PGE1 had developed to compensate the systemic and local side effects of PGE1. This study was proposed to determine whether Lipo-PGE1 administration enhanced the survival of composite graft through neovascularization quantitatively in a rabbit ear model. Methods: Fourteen New Zealand White Rabbits each weighing 3~4 kg were divided in two groups: (1) intravenous Lipo-PGE1 injection group and (2) control group. A $2{\times}1\;cm$ sized, full-thickness rectangular composite graft was harvested in each auricle. Then, the graft was reaaproximated in situ using a 5-0 nylon suture. For the experimental group, $3{\mu}g$/kg/day of Lipo-PGE1 ($5{\mu}g$/mL) was administered intravenously through the marginal vein of the ear for 14 days. The control group was received no pharmacologic treatment. On the 14th postoperative day, composite graft of the ear was harvested and immunochemistry staining used Monoclonal mouse anti-CD 31 antibody was performed. Neoangiogenesis was quantified by counting the vessels that showed luminal structures surrounded by the brown color-stained epithelium and counted from 10 random high-power fields (400x) by independent blinded observer. Statistical analysis (Wilcoxon Signed Ranks test for nonparametric data) was performed using SPSS v12.0, with values of p<0.05 considered significant. Results: The mean number of the microvessels was $15.48{\pm}8.65$ in the experimental group and $9.82{\pm}7.25$ in the control group (p=0.028). Conclusion: The use of Lipo-PGE1 facilitated the neoangiogenesis, resulted in the improvement of the survival rate of graft. On the basis of this results, we could support wider application of Lipo-PGE1 for more effective therapeutic angiogenesis and successful survival in various cases of composite graft in the human.

Keywords

References

  1. Koga T, Az-ma T, Yuge O: Prostaglandin E1 at clinically relevant concentrations inhibits aggregation of platelets under synergic interaction with endothelial cells. Acta Anaesthesiol Scand 46: 987, 2002 https://doi.org/10.1034/j.1399-6576.2002.460810.x
  2. Fantone JC, Kinnes DA: Prostaglandin E1 and prostaglandin I2 modulation of superoxide production by human neutrophils. Biochem Biophys Res Commun 113: 506, 1983 https://doi.org/10.1016/0006-291X(83)91754-0
  3. Rodriguez Vegas JM, Ruiz Alonso ME, Teran Saavedra PP: PGE-1 in replantation and free tissue transfer: early preliminary experience. Microsurgery 27: 395, 2007 https://doi.org/10.1002/micr.20377
  4. Mizushima Y, Yanagawa A, Hoshi K: Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. J Pharm Pharmacol 35: 666, 1983 https://doi.org/10.1111/j.2042-7158.1983.tb02862.x
  5. Lewis D, Goldztein H, Deschler D: Use of hyperbaric oxygen to enhance auricular composite graft survival in the rabbit model. Arch Facial Plast Surg 8: 310, 2006 https://doi.org/10.1001/archfaci.8.5.310
  6. Madeddu P: Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol 90: 315, 2005 https://doi.org/10.1113/expphysiol.2004.028571
  7. Moreschi D Jr, Fagundes DJ, Hernandes L, Haapalainen EF: Effects of prostaglandin E(1) in the genesis of blood capillaries in the ischemic skeletal muscle of rats: ultrastructural analysis. Ann Vasc Surg 22: 121, 2008 https://doi.org/10.1016/j.avsg.2007.07.035
  8. Seify H, Bilkay U, Jones G: Improvement of TRAM flap viability using human VEGF-induced angiogenesis: a comparative study of delay techniques. Plast Reconstr Surg 112: 1032, 2003 https://doi.org/10.1097/01.PRS.0000076186.97093.92
  9. Marra KG, Defail AJ, Clavijo-Alvarez JA, Badylak SF, Taieb A, Schipper B, Bennett J, Rubin JP: FGF-2 enhances vascularization for adipose tissue engineering. Plast Reconstr Surg 121: 1153, 2008 https://doi.org/10.1097/01.prs.0000305517.93747.72
  10. Kim EK, Hong JP: The effect of recombinant human erythropoietin on ischemia-reperfusion injury: an experimental study in a rat TRAM flap model. Plast Reconstr Surg 120: 1774, 2007 https://doi.org/10.1097/01.prs.0000287131.53488.c4
  11. Fan CL, Gao PJ, Gu YJ, Tang XF, Liu JJ, Wei J, Inoue K, Zhu DL: Therapeutic angiogenesis by intramuscular injection of fibrin particles into ischaemic hindlimbs. Clin Exp Pharmacol Physiol 33: 617, 2006 https://doi.org/10.1111/j.1440-1681.2006.04416.x
  12. Huang Y, Marui A, Sakaguchi H, Esaki J, Arai Y, Hirose K, Bir SC, Horiuchi H, Maruyama T, Ikeda T, Tabata Y, Komeda M: Sustained release of prostaglandin E1 potentiates the impaired therapeutic angiogenesis by basic fibroblast growth factor in diabetic murine hindlimb ischemia. Circ J 72: 1693, 2008 https://doi.org/10.1253/circj.CJ-07-0960
  13. Weiner R, Kaley G: Influence of prostaglandin E1 on the terminal vascular bed. Am J Physiol 217: 563, 1969
  14. Gensch C, Clever Y, Werner C, Hanhoun M, Bohm M, Laufs U: Regulation of endothelial progenitor cells by prostaglandin E1 via inhibition of apoptosis. J Mol Cell Cardiol 42: 670, 2007 https://doi.org/10.1016/j.yjmcc.2006.12.017
  15. Mehrabi MR, Serbecic N, Tamaddon F, Pacher R, Horvath R, Mall G, Glogar HD: Clinical benefit of prostaglandin E1-treatment of patients with ischemic heart disease: stimulation of therapeutic angiogenesis in vital and infarcted myocardium. Biomed Pharmacother 57: 173, 2003 https://doi.org/10.1016/S0753-3322(03)00026-X